Seminars in surgical oncology-Pancreas cancer adjuvant therapy trials

J Surg Oncol. 2021 May;123(6):1467-1474. doi: 10.1002/jso.26382.

Abstract

Adjuvant therapy for pancreatic cancer has undergone a paradigm shift in the last 30 years. Before the 1990s, surgery was the main treatment with high morbidity and minimal long-term survival. In the mid-1980s, GITSG showed a doubling of overall survival from 11 to 20 months with 5-fluorouracil-based chemoradiation and now the PRODIGE trial showed the benefit of FOLFIRINOX with the longest overall survival to date approaching 5 years. Further investigation on the agents, duration and sequencing of therapy remains ongoing.

Keywords: adjuvant chemoradiation; adjuvant chemotherapy; evidence-based medicine; pancreatic cancer.

Publication types

  • Review

MeSH terms

  • Carcinoma, Pancreatic Ductal / drug therapy
  • Carcinoma, Pancreatic Ductal / radiotherapy
  • Carcinoma, Pancreatic Ductal / surgery*
  • Carcinoma, Pancreatic Ductal / therapy*
  • Chemoradiotherapy, Adjuvant
  • Clinical Trials, Phase III as Topic
  • Humans
  • Neoadjuvant Therapy
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / radiotherapy
  • Pancreatic Neoplasms / surgery*
  • Pancreatic Neoplasms / therapy*
  • Randomized Controlled Trials as Topic
  • Surgical Oncology / methods